ak130
mAbexperimentalBi-specific
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2023 (NCT05653284)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07114315 | Phase 2 | Aug 31, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT06938321 | Phase 1/Phase 2 (Phase 2) | May 31, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT06530251 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT05653284 | Phase 1 | Jan 31, 2023 | Akeso Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 4 | 4 | 2 | 2023 |
1 organizations
Page 1 / 1